Open AccessImpact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
Author(s) -
Shari Goldfarb,
Volkan Turan,
Giuliano Bedoschi,
Enes Taylan,
Nadia Abdo,
Tessa Cigler,
Heejung Bang,
Sachinkumar Patil,
Maura N. Dickler,
Kutluk Oktay
Publication year - 2020
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-020-05933-7
Subject(s) - tamoxifen , ovarian reserve , anti müllerian hormone , medicine , breast cancer , chemotherapy , oncology , regimen , anthracycline , fertility preservation , cyclophosphamide , chemotherapy regimen , gynecology , cancer , hormone , fertility , pregnancy , infertility , biology , population , environmental health , genetics
To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on the reproductive potential of women with breast cancer by using a sensitive ovarian reserve marker anti-Mullerian hormone (AMH) as a surrogate.